艾沙康唑对29种致病酵母菌的MIC分布(2015-2017)
该研究采用EUCAST方法测定了1457株临床分离的29种酵母菌对艾沙康唑和氟康唑的MIC。结果显示艾沙康唑对常见念珠菌、隐球菌及多数罕见酵母菌有良好体外活性,但少数菌株MIC≥4 mg/L且对氟康唑耐药。
要点
- 艾沙康唑对常见念珠菌和隐球菌有良好体外活性。
- 少数常见念珠菌及罕见酵母菌可出现艾沙康唑MIC≥4 mg/L。
- Saprochaete clavata等罕见菌对艾沙康唑MIC50≥1 mg/L、MIC90≥4 mg/L。
核心结论
- 艾沙康唑对常见念珠菌、隐球菌及多数罕见酵母菌有良好体外活性。
- 部分罕见酵母菌对艾沙康唑MIC较高,可考虑为耐药。
研究设计与样本
- 研究采用EUCAST方法测定1457株临床分离酵母菌的艾沙康唑和氟康唑MIC。
- 菌株来自2015年1月至2017年10月法国国家参考中心,涵盖29种酵母菌。
- 菌种鉴定采用MALDI-TOF和分子方法。
主要发现
- 艾沙康唑对新型隐球菌MIC90 < 0.25 mg/L。
- 对白色念珠菌、光滑念珠菌、热带念珠菌、近平滑念珠菌和克柔念珠菌MIC90 ≤ 0.5 mg/L。
- 白色念珠菌0.7%(3/404)、光滑念珠菌2.7%(5/184)、热带念珠菌1.0%(1/96)和近平滑念珠菌0.8%(1/127)的菌株MIC ≥4 mg/L,且均对氟康唑耐药。
- 罕见菌中,Meyerozyma guilliermondii 8.7%(2/23)和Wickerhamomyces anomalus 10.0%(1/10)的菌株MIC ≥4 mg/L。
- Saprochaete clavata、Magnusiomyces capitatus和Rhodotorula mucilaginosa的MIC50 ≥1 mg/L、MIC90 ≥4 mg/L。
临床怎么用
- 艾沙康唑可用于常见念珠菌和隐球菌感染的体外活性参考。
- 对罕见酵母菌需关注艾沙康唑MIC,高MIC菌株可能耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Isavuconazole is a recent extended-spectrum triazole with activity against yeasts. However, few data are available about the in vitro activity of rare yeast species. We report the MIC distribution of isavuconazole compared with fluconazole for a large collection of common or rare yeasts. METHODS: Isavuconazole and fluconazole MICs were determined using the EUCAST method for 1457 clinical isolates, mainly recovered from invasive infections, belonging to 29 species. They were sent to the National Reference Centre for Invasive Mycoses & Antifungals between January 2015 and October 2017 and species identification was performed using a polyphasic approach (matrix-assisted laser desorption/ionization time of flight analysis and a molecular method). RESULTS: Isavuconazole had effective in vitro activity against Cryptococcus neoformans (MIC90 < 0.25 mg/L), the five most common Candida spp. (MIC90 ≤ 0.5 mg/L for Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, and Candida krusei) and also against the majority of rare species, including Candida kefyr and Candida lusitaniae. A few isolates of C. albicans (0.7%, 3/404), C. glabrata (2.7%, 5/184), C. tropicalis (1.0%, 1/96) and C. parapsilosis (0.8%, 1/127) exhibited MIC ≥4 mg/L. All were also resistant to fluconazole according to the EUCAST breakpoints. Some isolates with isavuconazole MIC ≥4 mg/L were also observed among rarer species: Meyerozyma guilliermondii (8.7%, 2/23), Wickerhamomyces anomalus (10.0%, 1/10). Other rare species Saprochaete clavata, Magnusiomyces capitatus, and Rhodotorula mucilaginosa had high MIC50 (≥1 mg/L) and MIC90 (≥4 mg/L) and could be considered as resistant to isavuconazole. CONCLUSIONS: We confirmed the good in vitro activity of isavuconazole against common Candida, Cryptococcus species and the majority of the rare yeast species studied.
引用
- Desnos-Ollivier M, Bretagne S, Boullié A, et al. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017). Clin Microbiol Infect. 2019. PMID: 30771532. doi:10.1016/j.cmi.2019.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。